Amwill Health Care Ltd

Amwill Health Care Ltd has announced that its Board of Directors will convene on October 23, 2026. The meeting agenda includes the consideration and approval of the Unaudited Financial Results for the half-year ended September 30, 2026 (H1 FY27). Additionally, the board will consider the declaration of an interim dividend for equity shareholders. The trading window for designated persons has been closed since October 1, 2026, and will reopen 48 hours after the financial results are announced.

Amwill Health Care Ltd has received a new import registration certificate from the Central Drugs Standard Control Organization (CDSCO) for its FoliColor- Oxidative hair colour products. The license, valid from October 8, 2026, to October 7, 2031, permits the company to import and commercially sell these cosmetic products in India. This approval is expected to expand the company's product portfolio and contribute to revenue growth. The license is a new grant and does not involve a related party.

Amwill Health Care Ltd has announced the closure of its trading window for designated persons, their immediate relatives, and other insiders. This closure is effective from October 1st, 2026, and will remain in effect until 48 hours after the declaration of the company's unaudited financial results for the half-year ending September 30th, 2026. In line with SEBI regulations, the PAN of designated persons will be frozen by the National Securities Depository Limited for trading in the company's equity shares during this period. The specific date for the board meeting to approve these financial results will be communicated separately. The company's website will also host this information.

Amwill Health Care Ltd has approved investments totaling INR 3 Crore from its internal accruals into two Alternative Investment Funds (AIFs). The company will invest up to INR 1.5 Crore in Vivriti Vihaan Trust and up to INR 1.5 Crore in Neo Income Plus Fund III. These investments are intended to support the company's long-term growth strategy and operational objectives, with contributions expected to positively impact financial growth. The investments are slated to be made in the upcoming months and do not involve any related party transactions.

Amwill Health Care Ltd announced the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for a further term of five years, effective January 27, 2027, until January 26, 2032. This decision was approved by the company's members at the 9th Annual General Meeting (AGM) held on August 14, 2026, through a special resolution. Both individuals are designated as Key Managerial Personnel and are not liable to retire by rotation. Mr. Tarun Gandhi brings over a decade of experience in financial management and business development, while Mr. Anand Gandhi has extensive experience in brand placement, marketing, and sales within the dermatology segment. The company confirmed that both directors are not debarred from holding office by any SEBI order or other authorities.

Amwill Health Care Ltd's Investment Committee has approved a hybrid treasury strategy to optimize surplus cash. The company will allocate funds across various investment avenues, including Government Securities (G-Secs), Treasury Bills, Government Bonds, Non-Convertible Debentures (NCDs), Commercial Papers, and Other Debt Securities up to ₹10 crore. Additionally, ₹2 crore is allocated for listed equity shares and IPO subscriptions, ₹15 crore for Private Credit Funds, Alternative Investment Funds (AIFs), Structured Debt Instruments, and other debt-oriented opportunities. Invoice discounting platforms and other investment opportunities will receive up to ₹3 crore, and Systematic Investment Plans (SIPs) in Mutual Funds will have a ceiling of ₹3 crore. This strategy aims to maintain liquidity and safety while seeking higher post-tax, risk-adjusted returns on excess capital. The investments do not involve any related party transactions.

Amwill Health Care Ltd announced board approval for the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors and Key Managerial Personnel. Their re-appointments are for a consecutive five-year period, commencing January 27, 2027, and concluding on January 26, 2032. This is subject to shareholder approval via special resolution at the upcoming 9th Annual General Meeting (AGM). The company also approved the Annual Report for FY2025-26, the convening of the 9th AGM on August 14, 2026, and set August 8, 2026, as the record date. The AGM will be conducted via Video Conferencing/Other Audio-Visual Means, with remote e-voting facilities provided by NSDL.

Amwill Health Care Ltd announced that its Investment Committee has approved opening a Fixed Deposit account with Vysya Co-operative Bank for ₹2 Crores. This investment, funded by internal accruals, is intended to support the company's long-term growth strategy. The transaction does not involve any related party. The disclosure is made in compliance with SEBI Listing Regulations and the details will be available on the company's website.

Amwill Health Care Ltd has announced its Ninth Annual General Meeting (AGM) for the Financial Year 2025-26, scheduled for Friday, August 14th, 2026, at 01:00 P.M. IST. The meeting will be conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM). The company will present audited financial statements for the year ended March 31, 2026, and propose a final dividend of ₹0.50 per equity share. Additionally, Ms. Sapna Parmar is proposed for re-appointment as a Director, and Mr. Tarun Gandhi for re-appointment as Managing Director. The cut-off date for determining shareholder eligibility for voting and attendance is Saturday, August 08th, 2026. Remote e-voting will be open from August 11th to August 13th, 2026.

Amwill Health Care Ltd has announced that the record date for determining eligibility for the final dividend for the financial year 2026 has been set as August 08, 2026. The company's Board of Directors, in a meeting held on July 17, 2026, also approved the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for five years starting January 27, 2027. Additionally, the Board approved the Annual Report for FY 2025-26, convened the 9th Annual General Meeting (AGM) for August 14, 2026, and set August 08, 2026, as the cut-off date for ascertaining voting rights at the AGM. The AGM will be conducted via Video Conferencing, with remote e-voting available from August 11 to August 13, 2026.